Nectin Therapeutics Licenses Novel Antibodies to Immunome

Nectin Contact: Fabian Tenenbaum Chief Executive Officer [email protected] +1 201 218-1774 SOURCE Nectin Therapeutics "Immunome believes the next generation of transformative antibody drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology," said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. "We appreciate the work Nectin has done on these antibodies and look forward to advancing them further." Under the terms of the agr ...